Across TCGA pan-cancer cohorts, IGFL1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGFL1 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IGFL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGFL1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC and SKCM are the cancer types where IGFL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.096	0.543	.028	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.683	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IGFL1 tumor-vs-normal RNA expression · all IGFL1 data types